In many cases, they can be used as soon as bone metastases are diagnosed. These drugs not only reduce the risk of fractures (a common complication) but may, in some cases, improve survival.

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...

Biotech’s radionuclide-drug conjugate SKB107 receives China NMPA approval to treat bone metastases in solid tumours: Chengdu, China Friday, March 28, 2025, 15:00 H ...

Promptly treating prostate cancer bone metastases with the newest medication can help change your prognosis dramatically, Tagawa says. “There are men who do well for decades,” he says.

If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more.

(the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-001 ...

Finally, because the median survival after developing bone metastases ranges from 6 to 48 months depending on tumor type, bone metastases cause chronic morbidity that often requires repeated ...

PET/CT scans using an experimental prostate-specific membrane antigen (PSMA) imaging agent can identify SC nodal metastasis ...

Currently, treatments for bone metastases of malignant tumors mainly include comprehensive treatments such as analgesic therapy, radiation therapy, bone-modifying drug therapy, and surgery.